CN108392626A - Pedf及其衍生物在制备重构冠状动脉储备性侧支微循环药物中的应用及其药物筛选方法 - Google Patents
Pedf及其衍生物在制备重构冠状动脉储备性侧支微循环药物中的应用及其药物筛选方法 Download PDFInfo
- Publication number
- CN108392626A CN108392626A CN201810174350.8A CN201810174350A CN108392626A CN 108392626 A CN108392626 A CN 108392626A CN 201810174350 A CN201810174350 A CN 201810174350A CN 108392626 A CN108392626 A CN 108392626A
- Authority
- CN
- China
- Prior art keywords
- acid
- collateral
- pedf
- drug
- microcirculation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 title claims abstract description 83
- 108090000102 pigment epithelium-derived factor Proteins 0.000 title claims abstract description 83
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 229940079593 drug Drugs 0.000 title claims abstract description 47
- 230000004089 microcirculation Effects 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000007877 drug screening Methods 0.000 title abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 37
- 230000002792 vascular Effects 0.000 claims abstract description 24
- 230000010412 perfusion Effects 0.000 claims abstract description 19
- 206010030113 Oedema Diseases 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 14
- 238000012216 screening Methods 0.000 claims abstract description 12
- 230000004217 heart function Effects 0.000 claims abstract description 9
- 238000001802 infusion Methods 0.000 claims abstract description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 67
- 150000003839 salts Chemical class 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000010171 animal model Methods 0.000 claims description 11
- 210000004351 coronary vessel Anatomy 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 150000007522 mineralic acids Chemical class 0.000 claims description 8
- 150000007524 organic acids Chemical class 0.000 claims description 8
- 230000008081 blood perfusion Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- -1 halogen acids Chemical class 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 239000001263 FEMA 3042 Substances 0.000 claims description 4
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 229960004365 benzoic acid Drugs 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002258 tannic acid Polymers 0.000 claims description 4
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 4
- 229940033123 tannic acid Drugs 0.000 claims description 4
- 235000015523 tannic acid Nutrition 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 229920000447 polyanionic polymer Polymers 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 7
- 239000012634 fragment Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 29
- 206010000891 acute myocardial infarction Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 16
- 206010061216 Infarction Diseases 0.000 description 14
- 230000007574 infarction Effects 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 210000004165 myocardium Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 230000036770 blood supply Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 230000003387 muscular Effects 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 101710186708 Agglutinin Proteins 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 101710146024 Horcolin Proteins 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 101710189395 Lectin Proteins 0.000 description 3
- 101710179758 Mannose-specific lectin Proteins 0.000 description 3
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 3
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 210000003191 femoral vein Anatomy 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 206010064966 Myocardial oedema Diseases 0.000 description 2
- 102100023087 Protein S100-A4 Human genes 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 102000008790 VE-cadherin Human genes 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 230000005961 cardioprotection Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001951 hemoperfusion Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002262 tip cell Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 150000002520 isoleucines Chemical class 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical group 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 150000002994 phenylalanines Chemical class 0.000 description 1
- 108010072683 pigment epithelium-derived factor receptor Proteins 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003588 threonines Chemical group 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 150000003680 valines Chemical group 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810174350.8A CN108392626B (zh) | 2018-03-02 | 2018-03-02 | Pedf及其衍生物在制备重构冠状动脉储备性侧支微循环药物中的应用及其药物筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810174350.8A CN108392626B (zh) | 2018-03-02 | 2018-03-02 | Pedf及其衍生物在制备重构冠状动脉储备性侧支微循环药物中的应用及其药物筛选方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108392626A true CN108392626A (zh) | 2018-08-14 |
CN108392626B CN108392626B (zh) | 2021-10-01 |
Family
ID=63092081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810174350.8A Active CN108392626B (zh) | 2018-03-02 | 2018-03-02 | Pedf及其衍生物在制备重构冠状动脉储备性侧支微循环药物中的应用及其药物筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108392626B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112390877A (zh) * | 2019-08-16 | 2021-02-23 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005100386A2 (en) * | 2004-04-08 | 2005-10-27 | Janssen Pharmaceutica N.V. | Canine cold-and menthol-sensitive receptor 1 |
CN106539790A (zh) * | 2016-12-02 | 2017-03-29 | 王海玲 | 一种治疗子宫内膜异位症的药物组合物 |
CN107602691A (zh) * | 2017-08-22 | 2018-01-19 | 徐州医科大学 | 色素上皮衍生因子的衍生多肽系列对于保护缺血心肌的用途 |
CN110664996A (zh) * | 2019-11-04 | 2020-01-10 | 徐州医科大学 | Pedf来源的多肽复合物在制备治疗肺癌药物中的应用 |
-
2018
- 2018-03-02 CN CN201810174350.8A patent/CN108392626B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005100386A2 (en) * | 2004-04-08 | 2005-10-27 | Janssen Pharmaceutica N.V. | Canine cold-and menthol-sensitive receptor 1 |
CN106539790A (zh) * | 2016-12-02 | 2017-03-29 | 王海玲 | 一种治疗子宫内膜异位症的药物组合物 |
CN107602691A (zh) * | 2017-08-22 | 2018-01-19 | 徐州医科大学 | 色素上皮衍生因子的衍生多肽系列对于保护缺血心肌的用途 |
CN110664996A (zh) * | 2019-11-04 | 2020-01-10 | 徐州医科大学 | Pedf来源的多肽复合物在制备治疗肺癌药物中的应用 |
Non-Patent Citations (6)
Title |
---|
INKA EITENMÜLLER 等: "The range of adaptation by collateral vessels after femoral artery occlusion", 《CIRC RES》 * |
JIALI CHEN 等: "Coronary Collateral Microcirculation Reserve Becomes Vestigial with Aging", 《CARDIOLOGY》 * |
QIXIANG ZHAO 等: "PEDF improves cardiac function in rats subjected to myocardial ischemia/reperfusion injury by inhibiting ROS generation via PEDF-R", 《INT J MOL MED》 * |
XIUCHENG LIU 等: "Native Coronary Collateral Microcirculation Reserve in Rat Hearts", 《J AM HEART ASSOC》 * |
XIUCHENG LIU 等: "Pigment Epithelium-Derived Factor Increases Native Collateral Blood Flow to Improve Cardiac Function and Induce Ventricular Remodeling After Acute Myocardial Infarction", 《XIUCHENG LIU 等》 * |
徐磊 等: "PEDF对大鼠缺血心脏功能的影响及相关机制的研究", 《徐州医学院学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112390877A (zh) * | 2019-08-16 | 2021-02-23 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108392626B (zh) | 2021-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jackson et al. | Thyrotropin-releasing hormone: abundance in the skin of the frog, Rana pipiens | |
Reed et al. | Blockade of beta 1-integrins in skin causes edema through lowering of interstitial fluid pressure. | |
US20070042016A1 (en) | Methods and Systems for Treating Injured Cardiac Tissue | |
CN107602691A (zh) | 色素上皮衍生因子的衍生多肽系列对于保护缺血心肌的用途 | |
US20070172472A1 (en) | Methods and Systems for Treating Injured Cardiac Tissue | |
Reid et al. | Physiological actions of the partially purified serum vasoconstrictor (serotonin). | |
US20100280493A1 (en) | Methods and Systems for Treating Injured Cardiac Tissue | |
CN110494154A (zh) | 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂 | |
Lee et al. | Effects of β‐endorphin on the contraction and electrical activity of the isolated perfused rat heart | |
CN108392626A (zh) | Pedf及其衍生物在制备重构冠状动脉储备性侧支微循环药物中的应用及其药物筛选方法 | |
CN101850124B (zh) | 白蛋白纳米-超声微泡载组织型纤溶酶原激活物基因靶向体系及其制备方法 | |
CN110483648A (zh) | 一种融合多肽及其应用 | |
Li et al. | VEGF mimetic peptide-conjugated nanoparticles for magnetic resonance imaging and therapy of myocardial infarction | |
CN114129295A (zh) | 一种新型经颈动脉注射脑转移瘤动物模型的构建方法 | |
EA019099B1 (ru) | Способ направленной доставки трансгена в миокард пациента с ишемией миокарда | |
SHIMADA et al. | Morphological studies of the cardiac lymphatic system | |
WO2007112136A2 (en) | Methods and systems for treating injured cardiac tissue | |
CN108410893A (zh) | 一种由NF-κB启动的肿瘤细胞特异效应基因表达载体及其表达产物和应用 | |
CN110437311A (zh) | 一种多肽及其应用 | |
WO2023185085A1 (zh) | Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途 | |
RU2388064C1 (ru) | Способ воспроизведения злокачественного процесса в эксперименте | |
Komorowska-Timek et al. | The effect of single administration of vascular endothelial growth factor or L-arginine on necrosis and vasculature of the epigastric flap in the rat model | |
CA3082421C (en) | C-met agonistic antibody and use thereof | |
CN104059154B (zh) | 一种新的具有抗心力衰竭作用的钠尿肽嵌合体cnaac | |
CN113143525A (zh) | 一种新型脑转移瘤动物模型的构建方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200604 Address after: No. 38, Hequn lane, Quanshan District, Xuzhou City, Jiangsu Province Applicant after: Chen Changshun Address before: 221000 No. 209 Copper Mountain Road, Jiangsu, Xuzhou Applicant before: XUZHOU MEDICAL University Applicant before: Dong Hongyan |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200713 Address after: Room 601, unit 3, building 2, 50 jiaheqian street, Quanshan District, Xuzhou City, Jiangsu Province Applicant after: Dong Hongyan Address before: No. 38, Hequn lane, Quanshan District, Xuzhou City, Jiangsu Province Applicant before: Chen Changshun |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230421 Address after: Floor 2, Building 10, Huaihai Health Industrial Park, No. 118 Huanghe West Road, Quanshan District, Xuzhou City, Jiangsu Province, 221000 Patentee after: Huarong (Xuzhou) Biomedical Technology Development Research Institute Co.,Ltd. Address before: Room 601, unit 3, building 2, 50 jiaheqian street, Quanshan District, Xuzhou City, Jiangsu Province, 221000 Patentee before: Dong Hongyan |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240507 Address after: Room 601, Unit 3, Building 2, No. 50 Jiaheqian Street, Quanshan District, Xuzhou City, Jiangsu Province, 221002 Patentee after: Dong Hongyan Country or region after: China Address before: Floor 2, Building 10, Huaihai Health Industrial Park, No. 118 Huanghe West Road, Quanshan District, Xuzhou City, Jiangsu Province, 221000 Patentee before: Huarong (Xuzhou) Biomedical Technology Development Research Institute Co.,Ltd. Country or region before: China |